Patents Assigned to E. R. Squibb and Sons, Inc.
  • Patent number: 5942406
    Abstract: Compositions and methods for avidin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin agarose during lyophilization and terminal sterilization processes. A dry composition, and wet compositions such as a gel, slurry or suspension having avidin immobilized on an inert support material are disclosed. The dry composition has at least 1000 biotin binding units of activity, and the wet compositions have at least 50 units of binding activity. These compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomer useful for fibrin sealants.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: August 24, 1999
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Steven James Burton, James C. Pearson, Peter A. D. Edwardson
  • Patent number: 5912010
    Abstract: Methods and devices for preventing and/or treating an adverse reaction of the skin to the presence of a skin-sensitizing and/or skin-irritating agent by administering an effective amount of a loop diuretic alone or in combination with at least one mast cell degranulator or at least one glucocorticosteroid.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: June 15, 1999
    Assignee: E.R. Squibb & Sons, Inc.
    Inventors: John J. Wille, Agis Kydonieus
  • Patent number: 5859239
    Abstract: Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme and neutral endopeptidase and thus useful as cardiovascular agents.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: January 12, 1999
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Donald S. Karanewsky, Jeffrey A. Robl
  • Patent number: 5859187
    Abstract: Inhibition of UL42 stimulation of herpesvirus DNA polymerase activity is exhibited by novel compounds of the formulasW'--A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --X ?SEQ. ID NO: 1!andY'--A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --A.sub.17 --Z ?SEQ. ID NO: 2!that are useful as antiviral agents.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: January 12, 1999
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: James T. Matthews, Katerina Leftheris, Robert K. Hamatake, John T. Stevens, Mary L. Haffey
  • Patent number: 5856477
    Abstract: The azepine intermediates of the formula ##STR1## wherein R.sub.6 and R.sub.7 are other than hydrogen are disclosed. These intermediates can be reacted with acylmercaptocarboxylic acids of the formula ##STR2## to give the pharmaceutically active products.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: January 5, 1999
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Jeffrey A. Robl
  • Patent number: 5856476
    Abstract: Processes are disclosed for preparing the azepine intermediates of the formula ##STR1## These intermediates can be reacted with acylmercaptocarboxylic acids of the formula ##STR2## to give the pharmaceutically active products.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: January 5, 1999
    Assignee: E. R. Squibbs & Sons, Inc.
    Inventor: Jeffrey A. Robl
  • Patent number: 5830496
    Abstract: A method of treating a wound comprising minimizing pressure on newly formed tissue around the perimeter of the wound by applying within the borders of the wound, a multi-layer laminate having a non-stretchable wound contact layer, a core layer comprising an absorbent material and a stretchable outer surface layer.
    Type: Grant
    Filed: February 4, 1997
    Date of Patent: November 3, 1998
    Assignee: E.R. Squibb & Sons, Inc.
    Inventor: Frank Freeman
  • Patent number: 5830200
    Abstract: It would be desirable to have improved designs of ostomy couplings which embody a springy or resilient split ring as a locking ring.In an ostomy coupling, first and second coupling members 50, 60 are held together by a springy flexible split locking ring 70. A plurality of tabs 71 symmetrically arranged on each limb of the locking ring 70, can be withdrawn generally radially outwardly by an upward pull on the locking ring to permit separation of the two coupling members. The ring 70 is generally circular in its unstressed condition.
    Type: Grant
    Filed: April 12, 1996
    Date of Patent: November 3, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Peter L. Steer, Keith G. M. Hollands, Graham Emery Steer, Ronald A. Plass, Howard Barratt
  • Patent number: 5827868
    Abstract: Thromboxane receptor antagonist activity is exhibited by compounds of the formula ##STR1## wherein: V is --(CH.sub.2).sub.m --, --O--, or ##STR2## but if V is --O--or ##STR3## R.sup.3 and R.sup.4 must complete an aromatic ring; W is --(CH.sub.2).sub.2 --, --CH.dbd.CH-- or phenylene;X is a single bond, --CH.dbd.CH--, --(CH.sub.2).sub.n --, or --O--(CH.sub.2).sub.n --; or X is branched alkylene or --O--branched alkylene wherein W is linked to Y through a chain n carbon atoms long;Y is --CO.sub.2 H, --CO.sub.2 alkyl, --CO.sub.2 alkali metal, --CH.sub.2 OH, --CONHSO.sub.2 R.sup.5, --CONHR.sup.6, or --CH.sub.2 -5-tetrazolyl;Z is O or NH;R.sup.3 and R.sup.4 are each independently hydrogen or alkyl or R.sup.3 and R.sup.4 together complete a ring optionally substituted through a ring carbon with a halo, lower alkyl, phenyl, halo (lower alkyl), halophenyl, oxo or hydroxyl group; and the remaining symbols are as defined in the specification.
    Type: Grant
    Filed: October 7, 1991
    Date of Patent: October 27, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Raj N. Misra, Jagabandhu Das, Steven E. Hall, Wen-Ching Han, Philip M. Sher, Philip D. Stein
  • Patent number: 5824230
    Abstract: A method and a device for separating a component, such as fibrin monomer from blood, by centrifugation, involve feeding of blood admixed an anticoagulant to a first annular chamber in a device, where the annular chamber is defined by a cylindrical outer wall and a cylindrical inner wall, both walls extending coaxially about a common axis, as well as by a top wall and a bottom wall. The top wall or the bottom wall is formed by a piston body displaceable within the first chamber. This method involves furthermore a centrifugation of the device about the said common axis to substantially separate blood into a cell fraction and a plasma fraction followed by the resulting plasma fraction being transferred while influenced by the piston body to a second chamber defined by an outer cylindrical wall. The outer cylindrical wall extends coaxially with the said common axis, whereby a fraction with fibrin I is caused to be separated in the second chamber while a suitable enzyme is being added.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: October 20, 1998
    Assignee: E.R. Squibb & Sons, Inc.
    Inventors: Niels Erik Holm, Peter A. D. Edwardson
  • Patent number: 5811292
    Abstract: Methods for the enzymatic resolution of mixtures of enantiomers, such as .beta.-lactam compounds, which may be employed as intermediates in the preparation of taxanes such as taxol, the latter useful in the pharmaceutical field.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: September 22, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Ramesh N. Patel, Laszlo J. Szarka, Richard A. Partyka
  • Patent number: 5801220
    Abstract: A rapid disintegrating and dispersing composition for thickening liquid waste into a thixotropic gel comprises a polymeric acrylic resin and a colloid-forming mixture of microcrystalline cellulose and sodium carboxymethylcellulose. Additional ingredients preferably used in making a tableted form of the composition include microcrystalline cellulose per se, polyvinylpolypyrrolidone, magnesium stearate and amorphous silica. The tablet is placed in suitable containment means such as a containment bag. The thixotropic properties of the composition enable the gelled waste to be restored to a liquid when small amounts of hand pressure are applied to the waste containment bag, thereby providing a convenient and simple means for disposal.
    Type: Grant
    Filed: November 1, 1995
    Date of Patent: September 1, 1998
    Assignee: E.R. Squibb & Sons, Inc.
    Inventors: Divyakant S. Desai, Ajit B. Thakur
  • Patent number: 5789197
    Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 4, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: John R. Wetterau, II, Daru Young Sharp, Richard E. Gregg
  • Patent number: 5776933
    Abstract: Novel aminediol compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds in inhibiting retroviral protease, particularly useful in the treatment and/or prevention of HIV infection (AIDS).
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: July 7, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Eric M. Gordon, Joel C. Barrish, Gregory S. Bisacchi, Chong-Qing Sun, Joseph A. Tino, Gregory D. Vite, Robert Zahler
  • Patent number: 5760036
    Abstract: Novel aminediol compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds in inhibiting retroviral protease, particularly useful in the treatment and/or prevention of HIV infection (AIDS).
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: June 2, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Eric M. Gordon, Joel C. Barrish, Gregory S. Bisacchi, Chong-Oing Sun, Joseph A. Tino, Gregory D. Vite, Robert Zahler
  • Patent number: 5741428
    Abstract: In a process of separating a liquid sample having phase portions of different densities by centrifugal separation, a phase separator container is employed. The phase separator container comprises a housing having concentric inner and outer cylindrical walls defining a longitudinal axis and a top wall and further a piston body constituting a bottom wall of the housing. The piston body defines together with the outer cylindrical wall, the inner cylindrical wall and the top wall, an annular chamber for receiving the liquid sample. The piston body is displaceable within the annular chamber for draining a phase portion separated from the liquid sample through a drain conduit means communicating with the annular chamber. The phase separation chamber further comprises a reaction chamber to which the phase portions exposed from the annular chamber is processed.
    Type: Grant
    Filed: October 31, 1996
    Date of Patent: April 21, 1998
    Assignee: E.R. Squibb & Sons, Inc.
    Inventor: Niels Erik Holm
  • Patent number: 5738784
    Abstract: A method and a device for separating a component, such as fibrin monomer from blood, by centrifugation, involve feeding of blood admixed an anticoagulant to a first annular chamber in a device, where the annular chamber is defined by a cylindrical outer wall and a cylindrical inner wall, both walls extending coaxially about a common axis, as well as by a top wall and a bottom wall. The top wall or the bottom wall is formed by a piston body displaceable within the first chamber. This method involves furthermore a centrifugation of the device about the said common axis to substantially separate blood into a cell fraction and a plasma fraction followed by the resulting plasma fraction being transferred while influenced by the piston body to a second chamber defined by an outer cylindrical wall. The outer cylindrical wall extends coaxially with the said common axis, whereby a fraction with fibrin I is caused to be separated in the second chamber while a suitable enzyme is being added.
    Type: Grant
    Filed: December 1, 1995
    Date of Patent: April 14, 1998
    Assignee: E.R. Squibb & Sons, Inc.
    Inventors: Niels Erik Holm, Peter A. D. Edwardson
  • Patent number: 5723609
    Abstract: Antiviral activity is exhibited by compounds having the formula ##STR1## and its pharmaceutically acceptable salts wherein R.sub.1 is ##STR2## wherein R.sub.2 is hydrogen, methyl, fluoro, chloro, bromo, iodo, hydroxy or amino; or trifluoromethyl; R.sub.5 is alkyl; R.sub.6 is hydrogen, alkyl, substituted alkyl, or aryl; and R.sub.7 and R.sub.
    Type: Grant
    Filed: March 13, 1989
    Date of Patent: March 3, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: William A. Slusarchyk, Robert Zahler
  • Patent number: 5723457
    Abstract: Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme and neutral endopeptidase and thus are useful as cardiovascular agents.
    Type: Grant
    Filed: July 8, 1996
    Date of Patent: March 3, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Donald S. Karanewsky, Jeffrey A. Robl
  • Patent number: 5723602
    Abstract: Compounds of the formula ##STR1## wherein X.sub.1 is ##STR2## are disclosed. These compounds possess inhibitory activity against angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) and are thus useful as cardiovascular agents.
    Type: Grant
    Filed: April 17, 1995
    Date of Patent: March 3, 1998
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Donald S. Karanewsky, Jeffrey A. Robl